Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients).

Delecoeuillerie, G; Joly, Philippe; Lara, A.; Paolaggi, J B

doi:10.1136/ard.47.9.733

Cited by 161 publications

(88 citation statements)

References 15 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A higher relapse rate after 2 months was observed in the low-dose group (65% vs 11%), while the adverse events were more common in patients treated with the higher dose (26% vs 0%) (9). Several retrospective studies analysed the outcome of patients treated with different initial GC doses, reporting divergent results (10)(11)(12)(13). One of these studies (n=132) observed a higher prevalence of adverse events (21% vs 3%) in patients treated with an initial dose of >15 mg prednisone per day compared to those receiving a lower dose (10).…”

Section: Reviewmentioning

confidence: 99%

Update on treatment of polymyalgia rheumatica

Camellino

Dejaco²

2018

Reumatismo

View full text Add to dashboard Cite

SUMMARYPolymyalgia rheumatica (PMR) is the second most common inflammatory rheumatic disease in the elderly after rheumatoid arthritis. It is clinically characterised by pain and stiffness in the neck, proximal shoulder and hip girdle. Glucocorticoids (GCs) are the cornerstone of PMR treatment, but they are associated with potentially severe side effects. Among GC-sparing agents, methotrexate revealed a modest benefit in clinical trials, and recently, there have been promising reports from tocilizumab. In this review, we summarize the available evidence on the treatment of PMR and the possible role in the future of other agents under investigation.

show abstract

Section: Reviewmentioning

confidence: 99%

Update on treatment of polymyalgia rheumatica

Camellino

Dejaco²

2018

Reumatismo

View full text Add to dashboard Cite

show abstract

“…Moreover, those patients commencing treatment with low doses of CS do not have more visual or neurological complications than patients treated with higher doses (264). Starting doses of 30-40 mg of prednisolone daily are thus recommended.…”

Section: Uncomplicated Gcamentioning

confidence: 99%

“…Both cumulative doses of CS and higher doses are associated with increased toxicity (265,266,267). Side effects may occur in at least one third of patients, and in two thirds if weight gain is included (264). Treatment with alternate-day CS administration is associated with a higher rate of treatment failure than is daily administration (268) and is not recommended.…”

Section: Uncomplicated Gcamentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and Treatment of Giant Cell Arteritis (Temporal Arteritis) – Past, Current and Future Aspects

Gran¹

2011

Advances in the Diagnosis and Treatment of Vasculitis

View full text Add to dashboard Cite

“…Of these, 15 received NSAIDs for less than three months and 12 for 9 7 months in average. The dose of NSAIDs in these 12 patients was constant throughout the study.…”

mentioning

confidence: 99%

Long term treatment of polymyalgia rheumatica with deflazacort.

Cimmino

Moggiana

Montecucco

et al. 1994

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

Deflazacort was administered at a mean starting dose of 21 8 mg/day with a range of 6-60 mg depending on severity of disease. The Results PATIENTSThe mean age of the 40 patients (24 women/ 16 men) was 70 7 years (range 50-91 years). Patients were referred 4-6 months after the onset of PMR on average (range 1-14 months).Twenty seven patients were allowed to continue treatment with NSAIDs at low doses. Of these, 15 received NSAIDs for less than three months and 12 for 9 7 months in average. The dose of NSAIDs in these 12 patients was constant throughout the study. FOLLOW UPTwo patients were lost to follow up on the first and third month. In the remaining 38 patients, the treatment lasted a mean of 18-9 months (range 9-48 months). Of the 23 patients with remission, seven required deflazacort for less than one year, and 20 for less than two years (fig 1). In these patients, the mean follow up after discontinuation of deflazacort was 9 9 months (range 1-33 months). The mean daily dose of deflazacort was 11-4 mg (range 2-5-32-2 mg) and the cumulative dose ranged between 0 9 g and 27 g (mean 6-6 g).Twenty three of 38 patients (60-5%) had no exacerbations; 13 patients had one exacerbation, 331 on 9 May 2018 by guest. Protected by copyright.

show abstract

Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients).

Cited by 161 publications

References 15 publications

Update on treatment of polymyalgia rheumatica

Update on treatment of polymyalgia rheumatica

Diagnosis and Treatment of Giant Cell Arteritis (Temporal Arteritis) – Past, Current and Future Aspects

Long term treatment of polymyalgia rheumatica with deflazacort.

Contact Info

Product

Resources

About